The smallest of all the pathogens, viruses, have continuously been the foremost 
strange microorganisms. Viral infections can cause extreme sicknesses as 
evidenced by the HIV/AIDS widespread or the later Ebola or Zika episodes. 
Apprehensive framework distortions are also regularly observed as consequences 
of numerous viral infections. Besides, numerous viral infections are of 
oncoviruses, which can trigger different types of cancer. Nearly every year, a 
modern infectious species emerges, debilitating the world population with an 
annihilating episode. Subsequently, there is a need to create antivirals to 
combat such rising infections. From the discovery of the antiviral drug 
Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was 
approved by the FDA in 2018, the whole process and criteria of creating 
antivirals have changed significantly. In this article, different auxiliary 
science strategies are described that can serve as a referral for therapeutic 
innovation.